implications of these findings here.
Fibroblasts are a major stromal cell type that is usually present within human epithelial carcinomas. The dominant contribution of these fibroblasts to the stroma has encouraged scientists to study the roles of stromal fibroblasts during tumor progression. For example, several research groups have determined whether stromal fibroblasts act to promote tumor growth and progression. Indeed, these studies demonstrated that stromal fibroblasts, specifically termed carcinoma-associated fibroblasts (CAFs), that have been extracted from human carcinomas mass can promote the growth of admixed epithelial carcinoma cells in immunodeficient mice, doing so far more potently than control fibroblasts extracted from non-cancerous tissues. Moreover, such CAFs showed an ability to inhibit cancer cell apoptosis, induce cancer cell proliferation, and stimulate tumor angiogenesis. 6, 7 Alpha-smooth muscle actin (α-SMA)-positive myofibroblasts have long been recognized as a prominent component of the activated fibroblasts present in both tumors and in sites of tissue injury. 8 Various growth factors, cytokines, and extra cellular matrix (ECM) proteins produced by myofibroblasts play pivotal roles in tissue repair by stimulating growth of nearby epithelial cells and facilitating angiogenesis. 7, 9 Such myofibroblasts secrete stromal cell-derived factor 1 (SDF-1), which is an angiogenic chemokine, in order to promote tumor growth and stimulate neoangiogenesis. 7, 10 In addition to α-SMA, various other markers have been used to detect stromal fibroblasts in tumors.
Included among these are vimentin, fibroblast-specific protein-1 (FSP-1/S100A4), 11 NG2 (Neuron-Glial Antigen-2), chondroitin sulfate proteoglycan, 5 PDGFR-β, 5 fibroblast-activation protein (FAP), 12 fibroblast-associated antigen, 13 prolyl 4-hydroxylase 14 (Fig. 1 ). Of these, α-SMA and FAP 12 are especially useful makers to resolve myofibroblasts in tumor stroma from stromal fibroblasts, whereas several of the other markers can be used to reveal both the myofibroblasts and fibroblasts that together form CAF populations ( Fig. 1 ).
Sugimoto and colleagues 5 Another example of the heterogeneity of stromal fibroblasts is provided by a subpopulation of SA-β -gal-positive, senescent fibroblast populations that are present among the stromal fibroblasts in human ovarian carcinomas; these senescent fibroblasts play pivotal roles in enhancing carcinogenesis through paracrine signaling mechanisms. 16, 17 In yet other studies, a mouse prostate tumor model indicates that carcinoma cells
Figure 1. Immunohistological markers of stromal fibroblasts in tumor
Carcinoma-associated fibroblasts (CAFs) are stromal fibroblast populations present within tumor and these CAFs include populations of both myofibroblasts and fibroblasts. Various fibroblastic markers are used to detect stromal fibroblasts in tumor: α-SMA, fibroblast-activation protein (FAP), vimentin, NG2 (Neuron-Glial Antigen-2) chondroitin sulfate proteoglycan, PDGFR-β, fibroblast-associated antigen, prolyl 4-hydroxylase, and fibroblast-specific protein-1 (FSP-1/S100A4). Of these, α-SMA and FAP seems to be specific markers for myofibroblasts.
prefentially induce the clonal expansion of a small fraction of fibroblasts that lack p53, eventually generating the majority stromal fibroblast population within a tumor; 18 this absence of p53 allowed stromal fibroblasts to generate highly proliferative fibroblasts, resembling CAFs, that further promote tumor progression. Supporting this line of observation, mutations of the p53 gene were indeed found in stromal regions microdisected from human breast carcinomas. 19 Further work will elucidate molecular mechanisms by which loss of p53 in stromal fibroblasts influences nearby epithelial carcinoma growth.
Stromal fibroblasts within tumors seem to be originally derived from heterogenous cell types that include bone marrow-derived progenitors, smooth muscle cells, preadipocytes, fibroblasts, and myofibroblasts. Sugimoto and colleagues' observation may reflect the various distinct cells-of-origin that have been responsible for generating stromal fibroblasts. Alternatively, a particular fraction of stromal fibroblasts might be selected or transdifferentiated into FSP-1-expressing cell populations during tumor progression. Ideally, future studies should address whether these FSP-1 + CAFs exist in human carcinomas in which they provide a tumor-promoting fraction.
Because stromal fibroblasts are genetically more stable than rapidly mutating tumor cell populations, tumor immunotherapy specifically targeting these fibroblasts expressing FAP-1 has been attempted and has been found to successfully attenuated tumor progression in mouse models 20, 21 In a larger sense, research on stromal fibroblasts will help us promote understanding of the complex tumor-stroma cell interactions in tumor-prone tissue microenvironments and will provide clues for the development of new types of anti-tumor therapeutics.
